408328-42-7

Basic information

• Product Name: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE
• Synonyms: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE
• CAS NO: 408328-42-7
• Molecular Formula: C₁₀H₈N₂O₂
• Molecular Weight: 188.18272
• Mol File: 408328-42-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE(408328-42-7)
• EPA Substance Registry System: 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE(408328-42-7)

Safety Data

• Hazardous Substances Data: 408328-42-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE is used as a building block in organic synthesis for the creation of complex organic molecules. Its cyclopropane ring and nitro-substituted nitrile group provide a stable and reactive platform for further functionalization and the formation of diverse chemical entities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE is utilized as a reagent in the synthesis of various drugs and pharmaceutical compounds. Its unique chemical structure allows for the development of novel therapeutic agents with potential applications in treating a wide range of diseases and medical conditions.
Used in Material Science:
1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE has potential applications in the development of new materials due to its unique chemical structure and reactivity. It can be used as a precursor or a component in the synthesis of advanced materials with specific properties, such as high thermal stability, electrical conductivity, or mechanical strength.
Used in Agrochemicals:
1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE can also be employed in the agrochemical industry for the synthesis of new pesticides, herbicides, or other crop protection agents. Its unique chemical properties may contribute to the development of more effective and environmentally friendly agrochemical products.
Used in Other Industrial Products:
Due to its versatility and reactivity, 1-(4-NITRO-PHENYL)-CYCLOPROPANECARBONITRILE has potential applications in various other industrial sectors. It can be used as a key intermediate or a building block in the synthesis of specialty chemicals, dyes, coatings, and other industrial products with specific performance characteristics.

Upstream product

• 555-21-5 4-Nitrophenylacetonitrile 
• 140-29-4 phenylacetonitrile 
• 935-44-4 1-cyano-1-phenylcyclopropane 
• 106-93-4 ethylene dibromide 

Downstream Products

• 23349-00-0 1-(4-nitrophenyl)-hydroxymethylcyclopropane 
• 1308814-98-3 ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate 
• 1308814-99-4 ethyl 1-(4-aminophenyl)cyclopropanecarboxylate 
• 1308815-00-0 ethyl 1-(4-((3-(1,3-dioxoisoindolin-2-yl)-2-hydroxypropyl)amino)phenyl)cyclopropanecarboxylate 
• 1308815-01-1 ethyl 1-(4-(5-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxooxazolidin-3-yl)phenyl)cyclopropanecarboxylate 
• 1308815-08-8 5-chloro-N-((3-(4-(1-(hydroxymethyl)cyclopropyl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide 
• 1308815-09-9 N-((3-(4-(1-(bromomethyl)cyclopropyl)phenyl)-2-oxooxazolidin-5-yl)methyl)-5-chlorothiophene-2-carboxamide 
• 1308814-51-8 5-chloro-N-((3-(4-(1-((dimethylamino)methyl)cyclopropyl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide 
• 1308815-10-2 ethyl 1-(4-(((benzyloxy)carbonyl)amino)phenyl)cyclopropanecarboxylate 
• 23348-98-3 methyl 1-(4-nitrophenyl)cyclopropanecarboxylate 
• 1308815-45-3 (1-(4-nitrophenyl)cyclopropyl)methylmethanesulfonate 
• 6921-44-4 4-nitrophenylcyclopropane 
• 1067192-46-4 N-[1-(4-nitro-phenyl)-cyclopropylmethyl]-acetamide 
• 23348-99-4 1-(4-nitrophenyl)cyclopropane-1-carboxylic acid 

Relevant articles and documents

COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS

The invention relates to compounds, in particular pyrimidine-2,4-diamines, analogues and salts thereof and pharmaceutical compositions comprising pyrimidine-2,4-diamines analogues and salts thereof for use in the treatment and prevention of a disease, in particular a growth hormone receptor-dependent condition. The invention also relates to methods of using these compounds and compositions to treat physiological dsorders related to the amount or activity of growth hormone. In a particular embodiment, the invention relates to a compound according to formula 1 for use in the treatment or prevention of a disease in a subject

Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation

Abstract: LSD1 is a lysine demethylase highly involved in initiation and development of cancer. To design highly effective covalent inhibitors, a strategy is to fill its large catalytic cleft by designing tranylcypromine (TCP) analogs decorated with long,

Preparation method of cycloalkane compound

The invention provides a preparation method of a cycloalkane compound, and concretely provides a new cycloalkane construction method for preparing a compound represented by formula I. The preparationmethod is green and environment-friendly.

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

Lewis Basic Sulfide Catalyzed Electrophilic Bromocyclization of Cyclopropylmethyl Amide

A Lewis basic sulfide catalyzed electrophilic bromocyclization of cyclopropylmethyl amide has been developed. The catalytic protocol is applicable to both 1,1- and 1,2-substituted cyclopropylmethyl amides, giving oxazolines and oxazines in good yields and excellent diastereoselectivity.

ROR-GAMMA MODULATORS AND USES THEREOF

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.

NOVEL ANTITHROMBOTIC AGENTS

The present invention relates to novel derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE

The present invention provides new compounds of formula I, wherein Q, R1, R2, R4, R5, R6, Xi, R7, R8, M and G1 nare defined as in formula I; invention compounds are modulators of follicle-stimulating hormone - ("FSH") which are useful for male and female contraception as well as other disorders modulated by FSH receptor.

COMPOUNDS AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.